|
| operating_income = | assets = | equity = | num_employees = 1681 (2015)〔 〕 | parent = | divisions = | subsid = | homepage = (www.bmrn.com ) | footnotes =〔BioMarin Pharmaceutical (BMRN) annual SEC income statement filing via Wikinvest.〕〔BioMarin Pharmaceutical (BMRN) annual SEC balance sheet filing via Wikinvest.〕 | intl = }} BioMarin Pharmaceutical Inc. is a biotechnology company based in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin develops and commercializes innovative biopharmaceuticals for serious, life-threatening rare diseases and medical conditions. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin is the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin is also the first company to provide therapeutics for phenylketonuria (PKU). ==History== BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999.〔 〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「BioMarin Pharmaceutical」の詳細全文を読む スポンサード リンク
|